Qianhong Pharmaceutical (002550.SZ) announced semi-annual results, with net profit of 153 million yuan to mother, a year-on-year decrease of 40.78%

According to Zhitong Finance App, Qianhong Pharmaceutical (002550.SZ) disclosed its 2026 semi-annual report. During the reporting period, the company achieved revenue of 758 million yuan, a year-on-year decrease of 12%; net profit attributable to shareholders of listed companies was 153 million yuan, a year-on-year decrease of 40.78%; deducted non-net profit of 142 million yuan, a year-on-year decrease of 28.46%; and basic earnings per share were 0.1215 yuan.

The main reason for the change in performance is due to the continued sluggish market demand in the global heparin API industry and the severe pharmaceutical ecological environment under the global high pressure situation, which has led to a sharp drop in the collective volume and price of heparin API products, leading to a continuous decline in overseas sales. Although sales in the domestic market are affected by the reduction in collection prices, thanks to years of technological quality improvements and brand influence, the sales volume and market share of major products have continued to increase, and the basic trend continues to improve, while overall sales performance in overseas markets is expected to stabilize and improve in the second half of the year.